In the final piece from "The Great Repricing" series, Bill Roth challenges seven foundational assumptions that have long guided pharmaceutical commercialization. From high-WAC/high-rebate launch strategies to the role of cash as a last resort, Bill argues that each no longer holds true in today's fragmented market. Drawing on the series' broader thesis that commercial, government, and cash now operate as distinct but interconnected payer economies, this installment explores what these shifting assumptions mean for how manufacturers price, launch, and manage products across their lifecycle. Rather than offering a single new pricing model to replace the old one, Bill uses this closing piece to push manufacturers to fundamentally rethink the playbook they've relied on for decades.